The dosage used in the clinical trial cited above was 1 serving (2
capsules) of Dysbiocide® along with 1 serving (1 capsule) of FCCidal™, taken twice per day. Due to the success of Dysbiocide®
and FC-Cidal™ in the clinical trial, clinicians have experimented
with administration options. This has led to an updated protocol
that combines Dysbiocide® and FC-Cidal™ with A.D.P.®. The
revised protocol includes the use of each of the three antimicrobials
at a dose of 2 capsules/tablets three times per day for 30 days.
Clinical Trial
In a 4-week clinical trial (Herbal Therapy Is Equivalent to Rifaximin for
the Treatment of Small Intestinal Bacterial Overgrowth) involving over
100 participants struggling with an overgrowth of bacteria in the
small intestines, several approaches were examined.24 One group
of participants received a commonly used medication for bacterial
overgrowth, while others were given an herbal protocol, which
included both Dysbiocide® and FC-Cidal™, administered as one
serving of each, twice per day.
By the end of the study, breath test results indicated normalization
in 46% of participants who had been assigned the herbal regimens.
The likelihood of improvement in this group was found to be
1.85-fold higher. This study suggests that herbal products like
Dysbiocide® and FC-Cidal™ may provide beneficial effects in
balancing microorganisms in the small intestines.*